Product Description
KER-012 is designed to bind to and inhibit the signaling of TGF-ß ligands, including activin A and activin B, which are key regulators of bone remodeling that act to suppress bone growth. (Sourced from: https://ir.kerostx.com/news-releases/news-release-details/keros-therapeutics-presents-results-preclinical-study-ker-012)
Mechanisms of Action: Activin A Inhibitor,Activin B Inhibitor
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Keros Therapeutics
Company Location: LEXINGTON MA 02421
Company CEO: Jasbir Seehra
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Brazil, France, Germany, Korea, Poland, Portugal, Spain, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TROPOS Study | P2 |
Completed |
Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension |
2025-03-05 |
12% |
| KER-012-A201 | P2 |
Completed |
Hypertension, Pulmonary |
2025-01-14 |